Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $98.8 million.

  • ARS Pharmaceuticals' Shares Outstanding (Weighted Average) rose 182.96% to $98.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.8 million, marking a year-over-year increase of 182.96%. This contributed to the annual value of $96.9 million for FY2024, which is 180.78% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $98.8 million, which was up 182.96% from $98.4 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $98.8 million during Q3 2025, and its lowest value of $28.9 million during Q4 2021.
  • For the 5-year period, ARS Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $69.9 million, with its median value being $94.9 million (2023).
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first tumbled by 1266.62% in 2022, then skyrocketed by 21076.65% in 2023.
  • Over the past 5 years, ARS Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $28.9 million in 2021, then soared by 38.39% to $40.0 million in 2022, then surged by 138.3% to $95.2 million in 2023, then grew by 1.81% to $96.9 million in 2024, then rose by 1.93% to $98.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $98.8 million for Q3 2025, versus $98.4 million for Q2 2025 and $98.1 million for Q1 2025.